LATEST NEWS AND EVENTS
Results of a clinical study called PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) found survival benefits for patients when compared to […]
The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for […]
ECAN Advocates Convince Congress to Include Esophageal Cancer in a Multi-Million Dollar Research Fund
Now it’s Time to Do It Again!
Thanks to thousands in the ECAN family, for the first time in history, Esophageal […]